Month: November 2022

Spinal Muscular Atrophy Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) – Evaluated by DelveInsight | Key Companies – Scholar Rock, Roche, Cytokinetics

The Spinal Muscular Atrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinal Muscular Atrophy pipeline products will significantly revolutionize the Spinal Muscular Atrophy market dynamics.

DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Spinal Muscular Atrophy, historical and forecasted epidemiology as well as the Spinal Muscular Atrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Spinal Muscular Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Spinal Muscular Atrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Muscular Atrophy Market Insights

 

Spinal Muscular Atrophy Overview

Spinal muscular atrophy (SMA) is an autosomal recessive rare neuromuscular disorder that is characterized by progressive muscle wasting because of the loss of motor neurons in the spinal cord (anterior horn), which controls voluntary muscle movement. Spinal Muscular Atrophy is one of the most common causes of infant death and mobility impairment. It mostly affects proximal muscles and respiratory muscles. The most common form of Spinal Muscular Atrophy is known as ‘5q SMA’ due to its genetic cause.

 

Some of the key facts of the Spinal Muscular Atrophy Market Report: 

  • The Spinal Muscular Atrophy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the National Organization for Rare Disorders (NORD), the prevalence of all types of SMA has been estimated to be 4-7.8 per 100,000 live births.
  • According to the study conducted by Lally et al., Spinal Muscular Atrophy genotype prevalence at birth consistently ranges from 8.5 — 10.3 per 100,000 live births, with a mid-range estimate of 9.4 per 100,000
  • Key Spinal Muscular Atrophy Companies: Scholar Rock, Roche, Cytokinetics, and others
  • Key Spinal Muscular Atrophy Therapies: Apitegromab, GYM329, Reldesemtiv, and others
  • The Spinal Muscular Atrophy epidemiology based on gender analyzed that Spinal Muscular Atrophy (SMA) occurs equally in men and women

 

Get a Free sample for the Spinal Muscular Atrophy Market Report- 

https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-market

 

Key benefits of the Spinal Muscular Atrophy Market report:

  1. Spinal Muscular Atrophy market report covers a descriptive overview and comprehensive insight of the Spinal Muscular Atrophy Epidemiology and Spinal Muscular Atrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Spinal Muscular Atrophy market report provides insights on the current and emerging therapies.
  3. Spinal Muscular Atrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Spinal Muscular Atrophy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Spinal Muscular Atrophy market.

 

Download the report to understand which factors are driving Spinal Muscular Atrophy epidemiology trends @ Spinal Muscular Atrophy Epidemiological Insights 

 

Spinal Muscular Atrophy Market  

The dynamics of the Spinal Muscular Atrophy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Spinal Muscular Atrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Spinal Muscular Atrophy Epidemiology Segmentation:

The Spinal Muscular Atrophy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Spinal Muscular Atrophy
  • Prevalent Cases of Spinal Muscular Atrophy by severity
  • Gender-specific Prevalence of Spinal Muscular Atrophy
  • Diagnosed Cases of Episodic and Chronic Spinal Muscular Atrophy

 

Spinal Muscular Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Muscular Atrophy market or expected to get launched during the study period. The analysis covers Spinal Muscular Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinal Muscular Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Spinal Muscular Atrophy market share @ Spinal Muscular Atrophy market forecast 

 

Spinal Muscular Atrophy Therapies and Key Companies

  • Apitegromab: Scholar Rock
  • GYM329: Roche
  • Reldesemtiv: Cytokinetics

 

Spinal Muscular Atrophy Market Drivers

  • Newborn Screening for Spinal Muscular Atrophy
  • Promising Upcoming Launches and Approval
  • Raising Awareness for Spinal Muscular Atrophy

 

Scope of the Spinal Muscular Atrophy Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Spinal Muscular Atrophy Companies: Scholar Rock, Roche, Cytokinetics, and others
  • Key Spinal Muscular Atrophy Therapies: Apitegromab, GYM329, Reldesemtiv, and others
  • Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
  • Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Spinal Muscular Atrophy Unmet Needs, KOL’s views, Analyst’s views, Spinal Muscular Atrophy Market Access and Reimbursement 

 

Spinal Muscular Atrophy Market Barriers

  • High-treatment Cost
  • Competition for Spinal Muscular Atrophy Emerging Therapies

 

Table of Contents 

1. Spinal Muscular Atrophy Market Report Introduction

2. Executive Summary for Spinal Muscular Atrophy

3. SWOT analysis of Spinal Muscular Atrophy

4. Spinal Muscular Atrophy Patient Share (%) Overview at a Glance

5. Spinal Muscular Atrophy Market Overview at a Glance

6. Spinal Muscular Atrophy Disease Background and Overview

7. Spinal Muscular Atrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinal Muscular Atrophy 

9. Spinal Muscular Atrophy Current Treatment and Medical Practices

10. Spinal Muscular Atrophy Unmet Needs

11. Spinal Muscular Atrophy Emerging Therapies

12. Spinal Muscular Atrophy Market Outlook

13. Country-Wise Spinal Muscular Atrophy Market Analysis (2019–2032)

14. Spinal Muscular Atrophy Market Access and Reimbursement of Therapies

15. Spinal Muscular Atrophy Market Drivers

16. Spinal Muscular Atrophy Market Barriers

17.  Spinal Muscular Atrophy Appendix

18. Spinal Muscular Atrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Spinal Muscular Atrophy treatment, visit @ Spinal Muscular Atrophy Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Market is Projected to Boost at a Moderate Growth Rate by (2022-2032) – Evaluated by DelveInsight | Key Companies – Scholar Rock, Roche, Cytokinetics

Hypercalcemia Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Crinetics Pharmaceuticals

The Hypercalcemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypercalcemia pipeline products will significantly revolutionize the Hypercalcemia market dynamics.

DelveInsight’s “Hypercalcemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hypercalcemia, historical and forecasted epidemiology as well as the Hypercalcemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Hypercalcemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Hypercalcemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypercalcemia Market Insights

 

Hypercalcemia Overview

Hypercalcemia is defined as serum calcium concentration two standard deviations above the mean values and is a common metabolic abnormality seen in both inpatient and outpatient settings. Depending on the serum calcium levels, hypercalcemia is categorized either as mild when levels are between 10 to12 mg/dL, moderate when levels are between 12 to 14 mg/dL, or severe when levels are more than 14 mg/dL.

 

Some of the key facts of the Hypercalcemia Market Report: 

  • The Hypercalcemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to the study conducted by Vakiti & Mewawalla, Hypercalcemia of malignancy occurs in approximately 20% of all cancer patients during their clinical course
  • According to the study conducted by Gastanaga et al., 2–3% of US cancer patients are affected by HCM each year. While Hypercalcemia is less common in prostatecancer and breast cancer, these patients make up 34% of cancer patients with Hypercalcemia
  • Key Hypercalcemia Companies: Crinetics Pharmaceuticals, and others
  • Key Hypercalcemia Therapies: Oral PTH antagonist, and others
  • The Hypercalcemia epidemiology based on gender analyzed that, no gender differences were found regarding hypercalcemia

 

Get a Free sample for the Hypercalcemia Market Report- 

https://www.delveinsight.com/sample-request/hypercalcemia-market

 

Key benefits of the Hypercalcemia Market report:

  1. Hypercalcemia market report covers a descriptive overview and comprehensive insight of the Hypercalcemia Epidemiology and Hypercalcemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Hypercalcemia market report provides insights on the current and emerging therapies.
  3. Hypercalcemia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Hypercalcemia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Hypercalcemia market.

 

Download the report to understand which factors are driving Hypercalcemia epidemiology trends @ Hypercalcemia Epidemiological Insights 

 

Hypercalcemia Market  

The dynamics of the Hypercalcemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032. 

“At present, Amgen, Kyowa Kirin Co., Ltd, and others are actively working towards the development of potential therapy to overcome the unmet medical needs of the currently used therapeutics. ”

 

Hypercalcemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hypercalcemia Epidemiology Segmentation:

The Hypercalcemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Hypercalcemia
  • Prevalent Cases of Hypercalcemia by severity
  • Gender-specific Prevalence of Hypercalcemia
  • Diagnosed Cases of Episodic and Chronic Hypercalcemia

 

Hypercalcemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypercalcemia market or expected to get launched during the study period. The analysis covers Hypercalcemia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hypercalcemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Hypercalcemia market share @ Hypercalcemia market forecast 

 

Hypercalcemia Therapies and Key Companies

  • Oral PTH antagonist: Crinetics Pharmaceuticals

 

Scope of the Hypercalcemia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hypercalcemia Companies: Crinetics Pharmaceuticals, and others
  • Key Hypercalcemia Therapies: Oral PTH antagonist, and others
  • Hypercalcemia Therapeutic Assessment: Hypercalcemia current marketed and Hypercalcemia emerging therapies
  • Hypercalcemia Market Dynamics: Hypercalcemia market drivers and Hypercalcemia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hypercalcemia Unmet Needs, KOL’s views, Analyst’s views, Hypercalcemia Market Access and Reimbursement 

 

Table of Contents 

1. Hypercalcemia Market Report Introduction

2. Executive Summary for Hypercalcemia

3. SWOT analysis of Hypercalcemia

4. Hypercalcemia Patient Share (%) Overview at a Glance

5. Hypercalcemia Market Overview at a Glance

6. Hypercalcemia Disease Background and Overview

7. Hypercalcemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hypercalcemia 

9. Hypercalcemia Current Treatment and Medical Practices

10. Hypercalcemia Unmet Needs

11. Hypercalcemia Emerging Therapies

12. Hypercalcemia Market Outlook

13. Country-Wise Hypercalcemia Market Analysis (2019–2032)

14. Hypercalcemia Market Access and Reimbursement of Therapies

15. Hypercalcemia Market Drivers

16. Hypercalcemia Market Barriers

17.  Hypercalcemia Appendix

18. Hypercalcemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Hypercalcemia treatment, visit @ Hypercalcemia Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hypercalcemia Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Crinetics Pharmaceuticals

Age-related Macular Degeneration Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion.

The Age-related Macular Degeneration market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Age-related Macular Degeneration pipeline products will significantly revolutionize the Age-related Macular Degeneration market dynamics.

DelveInsight’s “Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Age-related Macular Degeneration market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Age-related Macular Degeneration market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Age-related Macular Degeneration Market Insights

 

Age-related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries worldwide, with a profound effect on the quality of life of affected individuals. With the increase in life expectancy bringing growth in the number of reported cases, it adds a significant burden on the health care systems with the expensive current standard of care.

 

Some of the key facts of the Age-related Macular Degeneration Market Report: 

  • The Age-related Macular Degeneration market size was valued at USD 9.840 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The total prevalent cases of Age-related Macular Degeneration were approximately 51,743,361 in the 7MM, which might increase at a decent CAGR by 2032
  • The US accounted for approximately 17,282,569 prevalent cases of Age-related Macular Degeneration in the year 2021
  • In EU-5 countries the highest number of prevalent cases of Age-related Macular Degeneration was observed in Germany with 7,850,793 cases in the year 2021, followed by France
  • Key Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion., Evergreen Therapeutics, Ionis Pharmaceuticals, Roche, Luxa Biotechnology, Gemini Therapeutics, and others
  • Key Age-related Macular Degeneration Therapies: ALK-001, Pegcetacoplan, Zimura, Danicopan, EG-301, ONIS-FB-LRx, RPESC-RPE4W, GEM103, and others

 

Get a Free sample for the Age-related Macular Degeneration Market Report- 

https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market

 

Key benefits of the Age-related Macular Degeneration Market report:

  1. Age-related Macular Degeneration market report covers a descriptive overview and comprehensive insight of the Age-related Macular Degeneration Epidemiology and Age-related Macular Degeneration market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Age-related Macular Degeneration market report provides insights on the current and emerging therapies.
  3. Age-related Macular Degeneration market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Age-related Macular Degeneration market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Age-related Macular Degeneration market.

 

Download the report to understand which factors are driving Age-related Macular Degeneration epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights 

 

Age-related Macular Degeneration Market  

The dynamics of the Age-related Macular Degeneration market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

Age-related Macular Degeneration Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Age-related Macular Degeneration Epidemiology Segmentation:

The Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Age-related Macular Degeneration
  • Prevalent Cases of Age-related Macular Degeneration by severity
  • Gender-specific Prevalence of Age-related Macular Degeneration
  • Diagnosed Cases of Episodic and Chronic Age-related Macular Degeneration

 

Age-related Macular Degeneration Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Age-related Macular Degeneration market or expected to get launched during the study period. The analysis covers Age-related Macular Degeneration market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Age-related Macular Degeneration Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Age-related Macular Degeneration market share @ Age-related Macular Degeneration market forecast 

 

Age-related Macular Degeneration Therapies and Key Companies

  • ALK-001: Alkeus Pharmaceuticals
  • Pegcetacoplan: Apellis Pharmaceuticals
  • Zimura: Iveric Bio
  • Danicopan: Alexion.
  • EG-301: Evergreen Therapeutics
  • ONIS-FB-LRx: Ionis Pharmaceuticals/Roche
  • RPESC-RPE4W: Luxa Biotechnology
  • GEM103: Gemini Therapeutics

 

Age-related Macular Degeneration Market Drivers

  • Increasing prevalence of wet Age-related Macular Degeneration
  • Development in the field of gene therapy
  • Robust pipeline

 

Scope of the Age-related Macular Degeneration Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Age-related Macular Degeneration Companies: Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion., Evergreen Therapeutics, Ionis Pharmaceuticals, Roche, Luxa Biotechnology, Gemini Therapeutics, and others
  • Key Age-related Macular Degeneration Therapies: ALK-001, Pegcetacoplan, Zimura, Danicopan, EG-301, ONIS-FB-LRx, RPESC-RPE4W, GEM103, and others
  • Age-related Macular Degeneration Therapeutic Assessment: Age-related Macular Degeneration current marketed and Age-related Macular Degeneration emerging therapies
  • Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration market drivers and Age-related Macular Degeneration market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Age-related Macular Degeneration Unmet Needs, KOL’s views, Analyst’s views, Age-related Macular Degeneration Market Access and Reimbursement 

 

Age-related Macular Degeneration Market Barriers

  • High cost of Age-related Macular Degeneration treatment  
  • Competitive treatment landscape
  • Emerging biosimilar

 

Table of Contents 

1. Age-related Macular Degeneration Market Report Introduction

2. Executive Summary for Age-related Macular Degeneration

3. SWOT analysis of Age-related Macular Degeneration

4. Age-related Macular Degeneration Patient Share (%) Overview at a Glance

5. Age-related Macular Degeneration Market Overview at a Glance

6. Age-related Macular Degeneration Disease Background and Overview

7. Age-related Macular Degeneration Epidemiology and Patient Population

8. Country-Specific Patient Population of Age-related Macular Degeneration 

9. Age-related Macular Degeneration Current Treatment and Medical Practices

10. Age-related Macular Degeneration Unmet Needs

11. Age-related Macular Degeneration Emerging Therapies

12. Age-related Macular Degeneration Market Outlook

13. Country-Wise Age-related Macular Degeneration Market Analysis (2019–2032)

14. Age-related Macular Degeneration Market Access and Reimbursement of Therapies

15. Age-related Macular Degeneration Market Drivers

16. Age-related Macular Degeneration Market Barriers

17.  Age-related Macular Degeneration Appendix

18. Age-related Macular Degeneration Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Age-related Macular Degeneration treatment, visit @ Age-related Macular Degeneration Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Age-related Macular Degeneration Market to Observe Impressive Growth by (2022-2032), Evaluates DelveInsight | Key Companies – Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Alexion.

Atrial Fibrillation Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Atrial Fibrillation pipeline constitutes 5+ key companies continuously working towards developing 5+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Atrial Fibrillation Overview

 

Atrial Fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly out of coordination with the two lower chambers (the ventricles) of the heart.

 

“Atrial Fibrillation Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market. 

 

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. Atrial Fibrillation Key players such as – Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others, are developing therapies for the Atrial Fibrillation treatment 
  • Atrial Fibrillation Emerging therapies such as – ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.   
  • In January 2022, ARCA biopharma, Inc. announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society
  • A new patent issued to ARCA by the United States Patent and Trademark Office (USPTO) in February 2021 for use of Gencaro in treating AF in the HF population that ARCA plans to enroll in Gencaro’s planned Phase 3 development, a population that includes more than half of all HF patients in the United States and Europe 

 

Atrial Fibrillation Pipeline Therapeutics Assessment

  • Atrial Fibrillation Assessment by Product Type
  • Atrial Fibrillation By Stage and Product Type
  • Atrial Fibrillation Assessment by Route of Administration
  • Atrial Fibrillation By Stage and Route of Administration
  • Atrial Fibrillation Assessment by Molecule Type
  • Atrial Fibrillation by Stage and Molecule Type

 

DelveInsight’s Atrial Fibrillation Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

  • ESP-001: Espero BioPharma
  • CTP-Amio: Vivasc Therapeutics
  • HIP-2001: Hanmi Pharmaceutical
  • VE 1902: Verseon
  • HBI-3000: HUYA Bioscience
  • HSY 244: Novartis
  • AGN-151607: AbbVie
  • Gencaro: ARCA biopharma
  • Botulinum toxin A: Merz Pharma 

 

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Atrial Fibrillation treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
  • Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies

 

Atrial Fibrillation Pipeline Market Drivers

  • Rising prevalence of Atrial fibrillation
  • Increase in the Adoption of Advanced Technologies

 

Atrial Fibrillation Pipeline Market Barriers

  • Complications associated with the use of atrial fibrillation drugs
  • Lack of awareness regarding medical therapy in underdeveloped and developing regions

 

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Assessment- https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight

 

Scope of Atrial Fibrillation Pipeline Drug Insight    

  • Coverage: Global
  • Key Atrial Fibrillation Companies: Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, Verseon, HUYA Biosciences, Novartis, AbbVie, ARCA biopharma, Merz Pharma, and others
  • Key Atrial Fibrillation Therapies: ESP-001, CTP-Amio, HIP-2001, VE 1902, HBI-3000, HSY 244, AGN-151607, Gencaro, Botulinum toxin A, and others
  • Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
  • Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers 

 

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials

 

Table of Contents

1

Atrial Fibrillation Report Introduction

2

Atrial Fibrillation Executive Summary

3

Atrial Fibrillation Overview

4

Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5

Atrial Fibrillation Pipeline Therapeutics

6

Atrial Fibrillation Late Stage Products (Phase II/III)

7

Atrial Fibrillation Mid Stage Products (Phase II)

8

Atrial Fibrillation Early Stage Products (Phase I)

9

Atrial Fibrillation Preclinical Stage Products

10

Atrial Fibrillation Therapeutics Assessment

11

Atrial Fibrillation Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atrial Fibrillation Key Companies

14

Atrial Fibrillation Key Products

15

Atrial Fibrillation Unmet Needs

16 

Atrial Fibrillation Market Drivers and Barriers

17

Atrial Fibrillation Future Perspectives and Conclusion

18

Atrial Fibrillation Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atrial Fibrillation Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Bone Metastasis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Bone Metastasis pipeline constitutes 10+ key companies continuously working towards developing 10+ Bone Metastasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Bone Metastasis Overview

Bone metastasis occurs when cancer cells from other parts of the body spread to the bone. The most common area for bone metastasis is the spine. The first symptom a person might experience is bone pain.

 

“Bone Metastasis Pipeline Insight, 2022“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bone Metastasis Market. 

 

The Bone Metastasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Some of the key takeaways from the Bone Metastasis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Bone Metastasis treatment therapies with a considerable amount of success over the years. Bone Metastasis Key players such as – BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis, Mabwell (Shanghai) Bioscience Co., Ltd., Qilu Pharmaceutical Co., Ltd., and others, are developing therapies for the Bone Metastasis treatment 
  • Bone Metastasis Emerging therapies such as – BMD 3151, JMT103, ALMB-0168, Cabozantinib, MW032, QL1206, and others are expected to have a significant impact on the Bone Metastasis market in the coming years.   
  • Mabwell (Shanghai) Bioscience Co., Ltd. Initiated a Multi-center, Randomized,Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors 

 

Bone Metastasis Pipeline Therapeutics Assessment

  • Bone Metastasis Assessment by Product Type
  • Bone Metastasis By Stage and Product Type
  • Bone Metastasis Assessment by Route of Administration
  • Bone Metastasis By Stage and Route of Administration
  • Bone Metastasis Assessment by Molecule Type
  • Bone Metastasis by Stage and Molecule Type

 

DelveInsight’s Bone Metastasis Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Bone Metastasis Drugs Under Different Phases of Clinical Development Include:

  • BMD 3151: BiologicsMD
  • JMT103: Shanghai JMT-Bio Inc.
  • ALMB-0168: AlaMab Therapeutics
  • Cabozantinib: Exelixis
  • MW032: Mabwell (Shanghai) Bioscience Co., Ltd.
  • QL1206: Qilu Pharmaceutical Co., Ltd. 

 

Bone Metastasis Pipeline Analysis:

The Bone Metastasis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Bone Metastasis treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bone Metastasis Treatment.
  • Bone Metastasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Bone Metastasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bone Metastasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Bone Metastasis product details are provided in the report. Download the Bone Metastasis pipeline report to learn more about the emerging Bone Metastasis therapies

 

Bone Metastasis Pipeline Market Drivers

  • Rise in the number of cases of cancers worldwide
  • Development of promising circulating and tissue biomarkers

 

Bone Metastasis Pipeline Market Barriers

  • Lack of healthcare services in low-income countries
  • Lack of an effective multidisciplinary approach for treatment

 

Get a Free Sample PDF Report to know more about Bone Metastasis Pipeline Assessment- https://www.delveinsight.com/sample-request/bone-metastasis-pipeline-insight

 

Scope of Bone Metastasis Pipeline Drug Insight    

  • Coverage: Global
  • Key Bone Metastasis Companies: BiologicsMD, Shanghai JMT-Bio Inc., AlaMab Therapeutics, Exelixis, Mabwell (Shanghai) Bioscience Co., Ltd., Qilu Pharmaceutical Co., Ltd., and others
  • Key Bone Metastasis Therapies: BMD 3151, JMT103, ALMB-0168, Cabozantinib, MW032, QL1206, and others
  • Bone Metastasis Therapeutic Assessment: Bone Metastasis current marketed and Bone Metastasis emerging therapies
  • Bone Metastasis Market Dynamics: Bone Metastasis market drivers and Bone Metastasis market barriers 

 

Request for Sample PDF Report for Bone Metastasis Pipeline Assessment and clinical trials

 

Table of Contents

1

Bone Metastasis Report Introduction

2

Bone Metastasis Executive Summary

3

Bone Metastasis Overview

4

Bone Metastasis- Analytical Perspective In-depth Commercial Assessment

5

Bone Metastasis Pipeline Therapeutics

6

Bone Metastasis Late Stage Products (Phase II/III)

7

Bone Metastasis Mid Stage Products (Phase II)

8

Bone Metastasis Early Stage Products (Phase I)

9

Bone Metastasis Preclinical Stage Products

10

Bone Metastasis Therapeutics Assessment

11

Bone Metastasis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Bone Metastasis Key Companies

14

Bone Metastasis Key Products

15

Bone Metastasis Unmet Needs

16 

Bone Metastasis Market Drivers and Barriers

17

Bone Metastasis Future Perspectives and Conclusion

18

Bone Metastasis Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Bone Metastasis drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bone Metastasis Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Amana Global Partners closes its oversubscribed inaugural life sciences venture fund AGP Ventures LP

AGP Ventures LP secured commitments of more than the target size of US$ 50 Million in the fund and an additional US$ 50 Million for co-investments.

Mumbai, India – 30th November, 2022 – AGP Ventures LP is an early-stage life science venture fund, incorporated in the Cayman Islands, investing in disruptive technologies across segments like Genomics, Gene and Cell Therapies, Digital Health, Imaging, Diagnostics, AI, MedTech, Precision Medicines and others.

AGP Ventures LP provides an opportunity for family offices and institutional investors to invest alongside industry leaders in life sciences. The fund opens-up over 75 sought-after companies syndicate via combination of both high quality hard to access institutional level funds and direct investments globally. “AGP platform gives investor an ability to access few of the most exciting and disruptive investment opportunities duly vetted by our exceptional team,” said Sajal Heda, General Partner.

Managed by a team with combined life sciences and investment experience of 150+ years, the fund has global footprint with presence in Boston, New York, London, Riyadh, Dubai, Mumbai, and Taipei. Fund has an “information advantage” from the extensive network of corporates, venture managers and academia in the life sciences industry.  “With Limited Partners from Asia, Middle East and Europe, we are creating bridges between continents and pioneering regional eco-systems,” said Talal Al Ajou, General Partner.

AGP team has nuanced expectations of limited partners. “We differentiate ourselves in the industry by encouraging our limited partners to engage in therapeutic areas which are personal for them,” said Peter Savas, Venture Partner.

The Fund has already invested in five early-stage companies solving for the unmet clinical needs in areas like dopamine transporter brain imaging agent, multiplex gene editing and multiple precise genetic modifications for xenotransplantation, creating novel proteins with non-standard amino acids, revolutionize biopsy real-time assessment and engineered TCR-T cell therapies with cutting-edge synthetic biology and gene editing enhancements to target oncogenic driver mutations.

About Amana Global Partners

Amana Global Partners is a Cayman Island incorporated early-stage life sciences venture platform that invests alongside corporate venture groups, venture firms and top-tier investors with core thesis to invest in disruptive technologies and other fast growing life sciences sub-segments. Firm is co-founded by Sajal Jagdish Heda and Talal Marwan Al Ajou and has exceptional investment team with venture partners as Peter Savas and Paul Sekhri and advisory committee of notable industry experts.

Contact

Himannii Singhee, CFA, CAIA

h.singhee@amanagp.com

Media Contact
Company Name: AGP Ventures LP
Contact Person: Himannii Singhee
Email: Send Email
Phone: 00919920303936
City: Mumbai
State: Maharashtra
Country: India
Website: www.amanagp.com

Drug Eruptions Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

“DelveInsight Business Research LLP”
DelveInsight’s “Drug Eruptions Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Drug Eruptions, historical and forecasted epidemiology as well as the Drug Eruptions market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Drug Eruptions Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Drug Eruptions, historical and forecasted epidemiology as well as the Drug Eruptions market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Drug Eruptions market report provides current treatment practices, emerging drugs, Drug Eruptions market share of the individual therapies, and current and forecasted Drug Eruptions market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Drug Eruptions treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Drug Eruptions Overview

Acute or subacute adverse cutaneous reactions to a drug or medicine include drug eruptions. There are many types of drug eruption, which range from a clinically mild and unnoticed rash to a severe cutaneous adverse reaction (SCAR) that may be life-threatening. The most common drug eruptions are Morbilliform or exanthematous drug eruption angioedema (which rarely leads to anaphylaxis). Acute or subacute adverse cutaneous reactions to a drug or medicine include drug eruptions. There are many types of drug eruption, which range from a clinically mild and unnoticed rash to a severe cutaneous adverse reaction (SCAR) that may be life-threatening.

Drug Eruptions Epidemiology Insights:

  • Studies on Drug Eruptions, have provided important information on the type of reaction and the potentially causative drug but were not designed to investigate the incidence and prevalence of the reactions, which could therefore only be roughly estimated. 

  • Recently, two prospective trials on the epidemiology of drug eruption hospitals were carried out. The first (French) study analyzed cADRs after systemic intake or application of drugs in a specific hospital over a period of 6 months. All patients were examined by a dermatologist, and the drug use was evaluated by a pharmacologist. 

  • Based on 48 hospitalized patients in whom drug eruptions were diagnosed, a prevalence of 3.6 per 1,000 hospitalized patients was calculated. The second study was a prospective cohort study carried out in Mexico over a period of 10 months. 

  • This study demonstrated a prevalence of 7 per 1,000 hospitalized patients. In South Korea, a mandatory electronic reporting system for immunologically mediated drug eruptions could identify 2,652 cases of ADR in a total of 55,432 hospitalizations over a period of 7 months. 

  • The study included cutaneous as well as non-cutaneous reactions. An allergist classified 532 reactions to be “significant drug hypersensitivity reactions”. 100 of these were new events, and 70% of them had a cutaneous manifestation. The overall incidence of ADRs was estimated to be 1.8 per 1,000 hospitalizations.

Drug Eruptions Epidemiology Segmentation

 

  • Total Drug Eruptions patient segmentation 

  • Total  Drug Eruptions risk factors 

  • Total Drug Eruptions diagnostic cases 

  • Total Drug Eruptions treatment cases 

  • Total Drug Eruptions growth-related factors observed in patients 

Drug Eruptions Market Outlook 

The Drug Eruptions market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Drug Eruptions market trends by analyzing the impact of current Drug Eruptions therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Drug Eruptions market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Drug Eruptions market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Drug Eruptions market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Drug Eruptions Market Trends

 Drug Eruptions Key Companies 

  • Merck 

  • Pfizer

  • Bayer

  • Roch 

  • GSK

  • And many others 

 

Table of Contents

 

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of Drug Eruptions

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Drug Eruptions  Emerging Therapies

  9.  Drug Eruptions Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Market Drivers 

  12.  Market Barriers 

  13.  Appendix

  14.  Drug Eruptions Report Methodology

  15.  DelveInsight Capabilities

  16.  Disclaimer

Click here to read more about Drug Eruptions Market Trends

Media Contact
Company Name: DelveInsight
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Drug Eruptions Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Pollen Allergy Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

“DelveInsight Business Research LLP”
DelveInsight’s “Pollen Allergy- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pollen Allergy, historical and forecasted epidemiology as well as the Pollen Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Pollen Allergy- Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Pollen Allergy, historical and forecasted epidemiology as well as the Pollen Allergy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Pollen Allergy market report provides current treatment practices, emerging drugs, Pollen Allergy market share of the individual therapies, and current and forecasted Pollen Allergy market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Pollen Allergy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of Pollen Allergy Market Report:

  • In a study by Passali et al (2018), the prevalence of Allergic Rhinitis (AR) was reported to be 15%–25%. The most common aeroallergens were pollen and mites (67.31%). The tested pollens by the participants in the prick test included grass mix (32.69%), Artemisia vulgaris, Parietaria officinalis and Ambrosia eliator (15.38%), Betula verrucose or Betulaceae mix and Platanus occidentalis (13.46%), Cupressaceae (11.54%), and Oleaceae (9.62%).

  • According to Tanaka et al. (2012), the prevalence of AR and Japanese cedar pollinosis was 23.4% and 26.5%, respectively, in Japan. The prevalence rate of Japanese cedar pollinosis in children was reported to be in the range of 13.8% – 22.9%. The survey was executed in 407 to 510 children in May or June every year from 1995 to 2001. The prevalence rate of pollinosis was found to be related to the amount of pollen in the air. 

Key Benefits of the Report:

  • The report covers a descriptive overview of Pollen Allergy, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

  • Comprehensive insight has been provided into the Pollen Allergy epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Pollen Allergy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of Pollen Allergy market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pollen Allergy market

 

Got queries? Click here to know more about the  Pollen Allergy Market Landscape 

 

 

Pollen Allergy Overview

 

Pollen allergy, also called “hay fever” or “pollinosis”, is an allergic condition affecting the mucous membranes of the nose and the eyes. It is usually characterized by nasal discharge, nasal congestion, itchy, watery eyes, itchy nose, inner ears, and roof of the mouth. These symptoms are caused by a hypersensitivity to airborne pollen such as the pollen of trees, grasses, and weeds. 

 

The allergen comes in contact with cell-bound immunoglobulin E (IgE) in the tissues of the body’s conjunctiva and nasal mucosa, the tissues release mediators such as histamine or leukotrienes and induce annoying allergic symptoms. vAs with other allergies, the best treatment is to avoid the allergen. However, pollen is very difficult to avoid. If patients still experience symptoms despite taking these preventive measures, there are several over-the-counter (OTC) medications like antihistamines, such as cetirizine (Zyrtec) or diphenhydramine (Benadryl); decongestants, such as pseudoephedrine (Sudafed) or oxymetazoline (Afrin nasal spray); and medications that combine an antihistamine and a decongestant, such as Actifed (triprolidine and pseudoephedrine) and Claritin-D (loratadine and pseudoephedrine). 

Allergy shots are a form of immunotherapy that involves a series of injections of the allergen. The amount of allergen in the shot gradually increases over time. The shots modify the immune system’s response to the allergen, helping to reduce the severity of your allergic reactions. The patients experience complete relief within one to three years after starting allergy shots. The pollen allergies market is expected to witness market growth in the forecast period. The rise in the number of patients especially children suffering from pollen allergies would escalate the growth of the pollen allergies market

 

Pollen Allergy Epidemiology Insights: 

 

  • According to the World Allergy Organization (2016), in the International Study of Asthma and Allergies in Childhood (ISAAC), self-reported pollen allergy (hay fever) prevalence in 13- to 14-yr-old children was 22.1% as a global total. It differs among regions: 23.7% in Latin America, 33.3% in North America, 12.3% in Northern & Eastern Europe, and 21.2% in Western Europe.  

  • According to Centers for Disease Control and Prevention (2018), 19.2 million (7.6%) adults (18 and above) were diagnosed with hay fever, it was more prevalent in women (8.3%) than men (6.4%), while 5.2 million children (7.2%) were reported hay fever, it was more prevalent in boys (7.9%) than girls (6.4%).

 

Pollen Allergy Epidemiological Segmentation 

  • Pollen Allergy prevalent cases 

  •  Pollen Allergy gender-specific cases 

  • Pollen Allergy age-specific cases 

  • Pollen Allergy type-specific cases 

Pollen Allergy Market Outlook 

The Pollen Allergy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pollen Allergy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of the Pollen Allergy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

 

According to DelveInsight, the Pollen Allergy market in 7MM is expected to change in the study period 2019-2032.

 

Learn more by requesting for sample @ Pollen Allergy Market Landscape

Table of Contents

  1.  Key Insights 

  2.  Report Introduction 

  3.  Executive Summary of  Pollen Allergy Market 

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  The United States 

  7.  EU 5

  8.  Pollen Allergy Market  Emerging Therapies

  9.  Pollen Allergy Market Cancer Market Outlook

  10.  Market Access and Reimbursement of Therapies

  11.  Appendix

  12.  Pollen Allergy Market   Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

  15. About DelveInsight

Click here to read more about Pollen Allergy Market Landscape

Media Contact
Company Name: DelveInsight
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pollen Allergy Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Listeriosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

“DelveInsight Business Research LLP”
DelveInsight’s “Listeriosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Listeriosis, historical and forecasted epidemiology as well as the Listeriosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Listeriosis Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Listeriosis, historical and forecasted epidemiology as well as the Listeriosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Listeriosis market report provides current treatment practices, emerging drugs, Listeriosis market share of the individual therapies, and current and forecasted Listeriosis market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Listeriosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market

 

Some of the Key Facts of the Listeriosis Market Report:

 

  • Listeriosis is a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes. An estimated 1,600 people get listeriosis each year, and about 260 die.

  • Listeria monocytogenes is an uncommon human pathogen. It is mostly identified through cases of invasive disease, either associated with outbreaks or as sporadic infections, and through food safety programs. Nonperinatal cases of invasive listeriosis have an estimated worldwide incidence ranging from 0.1–1.1 cases per 105 population. CNS infections are present, on average, in 47% of infected patients with an average case-fatality rate of 36%). 

 

  •  The USDA issued 333 food recalls in the 5-year period from 2002 to 2006, 108 (32.4%) of which were due to L. monocytogenes. The quantity of meat and poultry involved ranged from 5 lbs (c. 2 kg) to 27 400 000 lbs (12 454 545 kg) per recall with a median of 1100 lbs (500 kg) per event. By comparison, the FDA issued 126 food product recalls or alerts in 2006 alone, 19 (15%) of which were due to L. monocytogenes. In these instances, bacteria were isolated from a diverse array of products including dairy (cheeses, raw milk), agricultural (strawberries, cut fresh fruit, sliced mushrooms), and various ready-to-eat foodstuffs such as coleslaw, crab dip, smoked salmon and turkey, egg salad, potato salad, and macaroni salad. The most commonly isolated bacteria belong to the serotypes 4b, 1/2a and 1/2b 

 

Key Benefits of the Listeriosis Market Report

 

  • The report covers the descriptive overview of Listeriosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

  • Comprehensive insight has been provided into the Listeriosis epidemiology and treatment in the 7MM

  • Additionally, an all-inclusive account of both the current and emerging therapies for Listeriosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

  • A detailed review of Listeriosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM

  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Listeriosis market

 

Got queries? Click here to know more about the Listeriosis Market Landscape

 

Listeriosis Overview

Listeriosis is a serious infection usually caused by eating food contaminated with the bacterium Listeria monocytogenes. An estimated 1,600 people get listeriosis each year, and about 260 die. The infection is most likely to sicken pregnant women and their newborns, adults aged 65 or older, and people with weakened immune systems. Listeriosis is usually diagnosed when a bacterial culture (a type of laboratory test) grows Listeria from body tissue or fluid, such as blood, spinal fluid, or the placenta. Invasive illness: People with an invasive illness are treated with antibiotics. Learn more about the treatment of people who have an invasive illness or who have a greater chance of developing one. Most people recover from intestinal illness without antibiotic treatment. Antibiotics are needed only for patients who are very ill or at risk of becoming very ill. People who have an intestinal illness should drink extra fluids when they have diarrhea.

Listeriosis Epidemiological Insights:

 

  •  137 (7.23%) of these samples were L. monocytogenes positive. The prevalence of L. monocytogenes in the animal samples was high (32.1%), and the main environmental source of prevalent genotypes in the three farms was silage. 

Listeriosis Epidemiological Segmentation 

  • Total Listeriosis prevelant cases 

  • Total Listeriosis diagnosed Cases 

  • Total Listeriosis treatment cases 

Listeriosis Market Outlook 

The Listeriosis market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Listeriosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

 

This segment gives a thorough detail of the Listeriosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Listeriosis market in 7MM is expected to change in the study period 2019-2032.

 

Learn more by requesting for sample @ Listeriosis Market Landscape

Table of Contents

 

  1.   Key Insights 

  2.   Report Introduction 

  3.   Executive Summary of Listeriosis  

  4.   Disease Background and Overview

  5.   Epidemiology and patient population

  6.   The United States 

  7.   EU 5

  8.   Listeriosis   Emerging Therapies

  9.   Listeriosis  Market Outlook

  10.   Market Drivers 

  11.   Market Barriers 

  12.   Market Access and Reimbursement of Therapies

  13.   Appendix

  14.   Listeriosis   Report Methodology

  15.   DelveInsight Capabilities

  16.   Disclaimer

  17.   About DelveInsight

Click here to read more about Listeriosis Market Landscape

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Listeriosis Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Back Posture Corrector Market is Anticipated Growing at a Steady Pace: Strategies & Insights by Credence Research

Some major players in the market are Aditya Birla Chemicals (India) Ltd., China Petrochemical Corporation (Sinopec Group), Lonza Group Ltd., Nikunj Chemical Limited, Nippon Soda Co. Ltd., Tianjin Kaifeng Chemical Co. Ltd.

The latest market report published by Credence Research Inc.is “Global Back Posture Corrector Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2028”. The global Back Posture Corrector market generated revenue of around USD () million in 2021 and is anticipated to grow a CAGR of over ()% during the forecast period from 2022 to 2028 to reach around USD () million in 2028.

The increasing back pain concerns due to prolonged sitting increasing the pressure on back muscles, leading to back pain, are the major factor in the growth of the back posture corrector market.  People sit for more hours to do work, which affects human health, such as discomfort, muscle tension and other things. Additionally, the increasing population and concern about their children’s health are expected to increase the growth of the back posture corrector market. The posture corrector also helps to prevent injuries while doing sports activities. These advantages are projected to drive the growth of the back posture corrector market. Furthermore, the rising awareness about the benefits of posture corrector and the increasing government support for research and development is also major factor of back posture corrector market growth. 

Browse Back Posture Corrector Market report- https://www.credenceresearch.com/report/back-posture-corrector-market

The global back posture corrector market is bifurcated into product, end-use, distribution channel, and geography. Based on product, the market is categorized into sitting support devices, posture braces, kinesiology tape, posture corrector clothing and others. Based on the end-use, the global market is segmented into men, women and kids. Based on the distribution channel, the global market is segmented into online and offline. The market is segmented based on geography: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Asia Pacific dominated for the largest share 2021 of the back posture corrector market. The Asia Pacific region has become a valuable market for leading the back posture corrector market because people from countries such as India, Japan and China are more concerned about their health. The Asia pacific countries stay healthy and avoid posture correctors due to focusing on physical exercises and gyms and others, which is increasing the growth of the back posture corrector market in the Asia Pacific region. Furthermore, the rising awareness about the posture corrector is increasing the growth. These factors are the growth of the Back Posture Corrector market in the Asia Pacific region.  

Why to Buy This Report-

  • The report provides a qualitative and quantitative analysis of the global back posture corrector market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, base year- 2021, and forecast period 2022-2028.
  • The report contains information related to the competitive landscape, like how the key players in the market are operating at a global, regional, and country level
  • In-depth analysis of the global back posture corrector market segmentation based on product, end-use and distribution channels.
  • Major countries in each region with their import/export statistics
  • The global back posture corrector market report also includes analyzing the global, regional, and country levels, along with key market trends, significant player analysis, market growth strategies, and key distribution channel areas.

Table Of Content:

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Research Methodology

1.3.1. Phase I – Secondary Research

1.3.2. Phase II-Primary Research

1.3.3. Phase III – Expert Panel Review

1.3.4. Approach Adopted

1.3.4.1. Top-Down Approach

1.3.4.2. Bottom-Up Approach

1.3.5. Assumptions

1.4. Market Segmentation

 

2. Executive Summary

2.1. Market Snapshot: Global Back Posture Corrector Market

2.2. Global Back Posture Corrector Market, By Product

2.3. Global Back Posture Corrector Market, By End-use

2.4. Global Back Posture Corrector Market, By Distribution Channel

2.5. Global Back Posture Corrector Market, By Region

 

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Back Posture Corrector Market Value, 2016-2028, (US$ Mn)

3.2. Market Dynamics

3.2.1. Key Growth Trends

3.2.2. Market Drivers

3.2.3. Market Restraints

3.2.4. Market Opportunities

3.2.5. Major Industry Challenges

3.3. Attractive Investment Proposition,2021

3.3.1. Product

3.3.2. End-use

3.3.3. Distribution Channel

3.3.4. Geography

 

4. Premium Insights

4.1. STAR (Situation, Task, Action, Results) Analysis

4.2. Porter’s Five Forces Analysis

4.2.1. Threat of New Entrants

4.2.2. Bargaining Power of Buyers/Consumers

4.2.3. Bargaining Power of Suppliers

4.2.4. Threat of Substitute Products

4.2.5. Intensity of Competitive Rivalry

4.3. Value Chain Analysis

4.4. Technology Analysis

4.5. Marketing Strategy Analysis

4.5.1. Online Marketing

4.5.2. Offline Marketing

4.5.3. Marketing Channel Development Trend

 

5. Market Positioning of Key Players, 2021

5.1. Company market share of key players, 2021

5.2. Competitive Benchmarking

5.3. Market Positioning of Key Vendors

5.4. Geographical Presence Analysis

5.5. Major Strategies Adopted By Key Players

5.5.1. Key Strategies Analysis

5.5.2. Mergers and Acquisitions

5.5.3. Partnerships

5.5.4. Product Launch

5.5.5. Geographical Expansion

5.5.6. Others

 

6. COVID-19 Impact Analysis

6.1. Global Back Posture Corrector Market Pre Vs Post COVID 19, 2019 – 2028

6.2. Impact on Import & Export

6.3. Impact on Demand & Supply

 

7. Global Back Posture Corrector Market

7.1. Global Back Posture Corrector Market, By Product, 2016-2028(US$ Mn)

7.1.1. Overview

7.1.2. Global Back Posture Corrector Market, By Product, 2021 vs 2028 (in%)

7.1.3. Global Back Posture Corrector Market, By Sitting support devices, 2016-2028 (US$ Mn)

7.1.4. Global Back Posture Corrector Market, By Posture Braces, 2016-2028 (US$ Mn)

7.1.5. Global Back Posture Corrector Market, By Kinesiology Tape, 2016-2028 (US$ Mn)

7.1.6. Global Back Posture Corrector Market, By Posture Corrector Clothing, 2016-2028 (US$ Mn)

7.1.7. Global Back Posture Corrector Market, By Others, 2016-2028 (US$ Mn)

7.2. Global Back Posture Corrector Market, By End-use, 2016-2028(US$ Mn)

7.2.1. Overview

7.2.2. Global Back Posture Corrector Market, By End-use, 2021 vs 2028 (in%)

7.2.3. Global Back Posture Corrector Market, By Men, 2016-2028 (US$ Mn)

7.2.4. Global Back Posture Corrector Market, By Women, 2016-2028 (US$ Mn)

7.2.5. Global Back Posture Corrector Market, By Kids, 2016-2028 (US$ Mn)

7.3. Global Back Posture Corrector Market, By Distribution Channel, 2016-2028(US$ Mn)

7.3.1. Overview

7.3.2. Global Back Posture Corrector Market, By Distribution Channel, 2021 vs 2028 (in%)

7.3.3. Global Back Posture Corrector Market, By Online, 2016-2028 (US$ Mn)

7.3.4. Global Back Posture Corrector Market, By Offline, 2016-2028 (US$ Mn)

…………………. toc continued

Browse Back Posture Corrector Market report- https://www.credenceresearch.com/report/back-posture-corrector-market

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, nonlegislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Recently Published Reports:

Vehicle Camshaft Market – Growth, Future Prospects & Competitive Analysis, 2016 – 2028 – https://www.credenceresearch.com/report/vehicle-camshaft-market

Trimmer Potentiometer Market – Growth, Future Prospects & Competitive Analysis, 2016 – 2028 – https://www.credenceresearch.com/report/trimmer-potentiometer-market

Media Contact
Company Name: Credence Research
Contact Person: Gunakesh Parmar
Email: Send Email
Phone: +91-8668442535
City: Gwalior
State: MP
Country: India
Website: https://www.credenceresearch.com/report/back-posture-corrector-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Back Posture Corrector Market is Anticipated Growing at a Steady Pace: Strategies & Insights by Credence Research